Cornerstone Wealth Group LLC Has $332,000 Stock Position in Thermo Fisher Scientific Inc. $TMO

Cornerstone Wealth Group LLC cut its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 24.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 820 shares of the medical research company’s stock after selling 269 shares during the period. Cornerstone Wealth Group LLC’s holdings in Thermo Fisher Scientific were worth $332,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TMO. Brighton Jones LLC grew its stake in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. GAMMA Investing LLC grew its stake in shares of Thermo Fisher Scientific by 22.0% during the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after purchasing an additional 877 shares during the period. Dynamic Advisor Solutions LLC acquired a new stake in shares of Thermo Fisher Scientific during the first quarter worth $2,218,000. Finally, Mission Wealth Management LP grew its stake in Thermo Fisher Scientific by 15.2% in the first quarter. Mission Wealth Management LP now owns 5,051 shares of the medical research company’s stock valued at $2,514,000 after acquiring an additional 668 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TMO has been the subject of a number of research analyst reports. William Blair initiated coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating for the company. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday. Evercore ISI boosted their target price on Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. Finally, Robert W. Baird boosted their target price on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $589.10.

Thermo Fisher Scientific Stock Performance

TMO opened at $525.08 on Wednesday. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $610.97. The firm has a market capitalization of $198.28 billion, a PE ratio of 30.37, a PEG ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The business’s 50-day simple moving average is $491.00 and its 200 day simple moving average is $448.20.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the prior year, the company posted $5.37 earnings per share. Thermo Fisher Scientific’s revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 400 shares of the business’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock worth $14,182,963. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.